Company intelligence / Profile preview
NeuroGeneration
Los Angeles, California, USAorpha.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuroGeneration has completed a Phase I clinical trial using adult-derived autologous neural stem cells for Parkinson’s disease. The company is preparing to initiate a Phase II study pending FDA approval. Its new Division of Biotherapeutics and Drug Discovery is expanding into molecular products targeting neuroprotective and endogenous repair mechanisms[1].
- Therapeutic areas
- Neurology
- Modalities
- Cellular therapies (adult neural stem cells)Biological modulators (drug discovery platforms)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NeuroGeneration.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroGeneration.